Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons.

Balijepalli, Chakrapani; Shirali, Rohan; Kandaswamy, Prashanth; Ustyugova, Anastasia; Pfarr, Egon; Lund, Søren S; Druyts, Eric

Balijepalli, Chakrapani; Shirali, Rohan; Kandaswamy, Prashanth; Ustyugova, Anastasia; Pfarr, Egon; Lund, Søren S; Druyts, Eric.

Afiliación

Balijepalli C; Precision Health Economics, Vancouver, BC, Canada. chakrapani.balijepalli@precisionxtract.com.
Shirali R; Precision Health Economics, Vancouver, BC, Canada.
Kandaswamy P; Boehringer Ingelheim GmbH, Ingelheim, Germany.
Ustyugova A; Boehringer Ingelheim GmbH, Ingelheim, Germany.
Pfarr E; Boehringer Ingelheim GmbH, Ingelheim, Germany.
Lund SS; Boehringer Ingelheim GmbH, Ingelheim, Germany.
Druyts E; Precision Health Economics, Vancouver, BC, Canada.

Diabetes Ther ; 9(4): 1491-1500, 2018 Aug.

Article en En | MEDLINE | ID: mdl-29949014

Palabras clave

Cardiovascular outcomes; DPP-4 inhibitors; Empagliflozin; Network meta-analysis; Saxagliptin; Sitagliptin

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Diabetes Ther Año: 2018 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google